Apigenin

Speaker 1...So, apigenin, it’s a flavone, a type of plant pigment. You find it in chamomile, parsley, celery. But why are longevity researchers so interested in it?

Speaker 2It boils down to its role as a CD38 inhibitor. CD38 is an enzyme, and its primary job is to break down NAD⁺, a coenzyme critical for countless cellular processes, including energy production and DNA repair.

Speaker 1Right, and NAD⁺ levels naturally decline as we age. So, if CD38 is breaking it down, then inhibiting CD38 could help preserve NAD⁺.

Speaker 2Exactly. By inhibiting CD38, apigenin essentially slows that NAD⁺ breakdown, potentially helping maintain higher NAD⁺ levels. This is why it’s often discussed within the context of the NAD⁺/Sirtuin axis, a key pathway in aging research.

Speaker 1So, the idea is that by preserving NAD⁺, you're supporting these vital cellular functions that tend to falter with age. But is this effect proven in humans?

Speaker 2That's the big question. While *in vitro* and animal studies, like one in *Nature Communications* in 2020, show promising results regarding CD38 inhibition and NAD⁺ preservation, we still lack robust human clinical trials specifically demonstrating apigenin’s impact on human NAD⁺ levels and subsequent longevity outcomes.

Speaker 1So, for now, it's a fascinating molecule because of its mechanism, but we’re waiting on more human data to confirm its broader longevity benefits.

Speaker 2Precisely. It highlights an important area of research, but the direct, long-term impact on human aging is still unproven.

Speaker 1...and that’s where apigenin comes in, a flavone that’s been touted for its potential to inhibit CD38.

Speaker 2Right, and CD38 is a major consumer of NAD⁺, so the idea is that by inhibiting CD38, apigenin helps preserve NAD⁺ levels, which are crucial for the sirtuin pathway and overall cellular health. It sounds great in theory, but what’s the human evidence?

Speaker 1That’s the critical question. A lot of the initial excitement stemmed from *in vitro* and animal studies, which showed promising results regarding CD38 inhibition and NAD⁺ preservation.

Speaker 2But translating that to humans can be tricky. Have we seen those same benefits manifest in clinical trials for longevity or healthspan markers?

Speaker 1Well, direct human clinical trials specifically on apigenin's *longevity* effects via NAD⁺ preservation are still quite limited. For example, a study in *Food & Function* in 2020 explored apigenin’s bioavailability and some inflammatory markers, but not direct NAD⁺ effects in healthy older adults.

Speaker 2So, while we understand the mechanism – apigenin as a CD38 inhibitor, preserving NAD⁺ – the *human evidence* demonstrating that this translates into significant, measurable improvements in age-related biomarkers or health outcomes is largely still unproven. We don't have those large, long-term trials yet, showing it actually impacts aging pathways in people as profoundly as some hope.

Speaker 1Exactly. It's a fascinating molecule with a clear biological rationale, but we need to distinguish between what the lab and animal studies suggest, and what robust human clinical data actually *shows* regarding its impact on NAD⁺ and longevity. A lot remains unknown.

Speaker 1...and that’s where apigenin comes in. It’s a flavone, and studies show it acts as a CD38 inhibitor.

Speaker 2So, it helps maintain NAD⁺ levels? That's the big takeaway?

Speaker 1Precisely. By inhibiting CD38, apigenin effectively slows down the breakdown of NAD⁺, thus helping to preserve its levels in the body. This is a key part of the NAD⁺/Sirtuin axis, a pathway of significant interest in longevity research.

Speaker 2We've seen some promising cell and animal studies on CD38 inhibition and NAD⁺ preservation. For example, a paper in *Nature Metabolism* in 2019 really highlighted the potential.

Speaker 1Yes, fascinating stuff. But it also raises an important question: what don't we know yet about apigenin specifically in humans for this purpose?

Speaker 2That's the open question, isn't it? While the mechanism of action is fairly well-established – apigenin inhibiting CD38 – we still lack robust, large-scale human trials directly demonstrating its long-term impact on NAD⁺ levels and subsequent health outcomes.

Speaker 1Exactly. We understand the *how* it works at a molecular level, but the *what it does* for human longevity in a measurable way, over time, that's still largely unproven. Are there optimal dosages? Are there specific populations who might benefit more?

Speaker 2And what about potential side effects or interactions? The current evidence is suggestive, but for now, we're talking about a promising molecule within a complex pathway, not a definitive longevity intervention. More research is definitely needed before we can draw firm conclusions for human application.